Abbott’s Simcor Wins FDA Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of lipid-lowering agent is due before the end of this year's first quarter
You may also be interested in...
Payer Cost Strategies Weigh On CV Fixed-Dose Combinations
Fixed-dose combination drugs represent an attractive marketing prospect for drug makers given their relative low development cost and the opportunity they represent to extend a brand's lifecycle
Payer Cost Strategies Weigh On CV Fixed-Dose Combinations
Fixed-dose combination drugs represent an attractive marketing prospect for drug makers given their relative low development cost and the opportunity they represent to extend a brand's lifecycle
Abbott Won’t Shrink From Competitor Merck’s Cordaptive
Merck’s niacin/laropiprant combination will compete against Abbott’s Niaspan after it is approved by FDA.